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Metabolism of apolipoprotein B-containing lipoproteins In subjects with
nephrotic-range proteinurla. Although hyperlipidemia is a well recog-
nized complication of the nephrotic syndrome, the precise disturbances
of lipoprotein metabolism which cause the elevated plasma lipid and
lipoprotein concentrations have not been clearly defined in humans.
This study examines the metabolism of apolipoprotein B-containing
lipoproteins in patients with nephrotic-range proteinuria and in healthy
controls. Two radioiodinated tracers of very low density lipoproteins
(VLDL1, Sf60 to 400, and VLDL2, Sf20 to 60), were used to trace the
metabolism of apolipoprotein B through the delipidation cascade from
very low density lipoproteins (VLDL) to low density lipoproteins
(LDL). The data from the apoB specific radioactivity curves and the
pool sizes of apoB in four subfractions were analyzed by a multicom-
partmental modeling procedure using the SAAM 30 program. The main
findings in the nephrotic group were: I.) a consistent decrease in the
fractional rate of apoB transfer from VLDL—VLDL2 (median val-
ues—nephrotic 0.92 pools/day vs. controls 3.66, P < 0,02) and from
VLDL2—*IDL (1.49 vs. 2.74, P < 0.05); 2.) increased secretion of apoB
into VLDL2 (14.5 mg/kg/day vs. 4.2, P < 0.02); 3.) a trend towards
decreased removal of IDL and LDL attributable to a defect in LDL
receptor-mediated removal as previously shown (Metabolism 39:187—
192, 1990). These findings suggest that catabolic defects of the apo
B-containing lipoproteins are as important as increased hepatic synthe-
sis in the pathogenesis of nephrotic hyperlipidemia in humans.
Hyperlipidemia has long been recognized as a complication
of human nephrotic syndrome. However, the metabolic
changes which result in the elevations of plasma lipids and
lipoproteins have not been satisfactorily established [1, 2].
Evidence from experimental animal models of nephrotic syn-
drome has demonstrated increased hepatic lipoprotein secre-
tion as the major cause of the hyperlipoproteinemia with some
contribution from delayed lipoprotein catabolism [3]. It is not
certain, however, that these findings can be extrapolated to
humans. In recent years a considerable body of information
regarding normal and abnormal lipoprotein metabolism has
been obtained from techniques which employ radiolabeled
tracers to follow the fate of lipoprotein particles in vivo [4].
Despite a number of early studies in nephrotic syndrome [5—8],
these methods have not been widely employed to investigate
this form of secondary hyperlipidemia.
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Hyperlipidemia in nephrotic syndrome may take various
forms [1]. The most common finding is an elevation of low
density lipoprotein (LDL) cholesterol levels. In more severe
cases with heavy proteinuria and severe hypoalbuminemia,
hypertriglyceridemia and elevated very low density lipoprotein
(VLDL) cholesterol levels may become the dominant abnor-
malities [9, 10]. High density lipoprotein (HDL) cholesterol
levels have been variously recorded as high, low or normal [11,
12]. The main abnormalities therefore involve the apolipopro-
tein B-containing lipoproteins. In the general population this
pattern is associated with an increased risk of coronary ather-
osclerosis. Patients with nephrotic syndrome and/or renal fail-
ure are considered to have an increased incidence of ischemic
heart disease [13], although this has been challenged by some
[14] and the benefits of lipid-lowering therapy have not been
clearly shown. Recent interest has also focused on the possible
role of hyperlipidemia in the progression of many renal diseases
[15, 16]. A clearer understanding of the pathophysiological
disturbances of lipoprotein metabolism may allow more precise
targeting of future therapeutic efforts to reduce the hyperlipi-
demia.
The kinetic characteristics of very low and low density
lipoproteins can be followed by trace-labeling of the apoB
moiety. Each particle contains one molecule of apoB which is
integral to its structure and remains with the lipoprotein during
its lifetime in the circulation. Radiolabeled apoB can therefore
be used to follow the metabolic fate of lipoprotein particles.
Recent reports have examined LDL apoB kinetic studies in
patients with nephrotic syndrome and hypercholesterolemia
[17, 18]. In our own study of the condition we concluded, on the
basis of experiments using dual tracer methods, that the main
reason for an increased LDL apoB pool in nephrotic syndrome
was a reduced clearance (that is, fractional catabolic rate) of
LDL by the receptor-mediated pathway [19]. Synthetic rates
were increased only in those patients with proteinuria in excess
of 10 g/day. There is little data on the metabolism of apoB in
VLDL. In a recent report of four nephrotic subjects Vega and
Grundy found delayed catabolism of VLDL with normal pro-
duction rates [17]. However, these workers used a tracer of a
wide density range which included both VLDL and IDL parti-
cles. Since there is considerable heterogeneity in the metabo-
lism of VLDL particles, more precise information may be
obtained by using tracers with well-defined flotation character-
istics [20].
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Table 1. Clinical characteristics of nephro tic groupa
Body mass Duration of
Age Weight index disease
Subject Sex years kg kg/rn2 Histology months Treatment
CM M 60 77 26.3 FGSb 310 Nifedipine, metoprolol,
ranitidine
AP M 55 98 30.9 Membranous 42 Frusemide, atenolol, nifedipine
WS M 58 75 27.9 Membranous 55 Atenolol, enalapnl, warfarin
JH M 53 90 29.4 IgA 10 Digoxin, bumetanide, warfarin
JO M 48 57 24.1 Membranous 420 Nifedipine, atenolol, frusemide
MD F 28 49 19.4 MCGNC II 159 Phenobarbitone
RG M 66 80 25.0 Membranous 31 Nifedipine
CF F 34 61 22.6 MCGN II 66 Frusemide
a Control group: N = 5, M:F = 3:2, age 36 to 46 years, weight 71 to 89 kgb Focal glomeruloscierosis
Mesangiocapillary glomerulonephritis
Table 2. Renal function tests
Serum Serum Creatinine Quantitative
Subject
creatinine
umol/liter
albumin
glliter
clearance rn/I
minll.73 m2
proteinuria
giday
CM 310 33 19 6.6
AP 190 36 35 10.8
WS 160 33 43 6.1
JH 100 38 58 3.3
JG 42( 32 18 9.6
MD 90 33 90 6.2
RU 250 27 40 8.3
CF 70 31 89 4.5
Values represent mean of repeated measures over the study period.
O Serum creatinine rose from 370 to 450 smo1/liter over the study
period.
The aim of this study was to investigate the metabolism of the
apoB moiety of very low density lipoproteins in patients with
nephrotic syndrome. Quantitative assessments of apoB produc-
tion, catabolism and flux through the delipidation cascade from
VLDL to LDL were derived from multicompartmental analysis
of apoB pool sizes and plasma decay/appearance curves.
Methods
Patients
Patients were recruited from the outpatient clinic of the renal
unit at Glasgow Royal Infirmary according to the following
selection criteria: 1.) quantitative proteinuria > 3.0 g/day; 2.)
serum creatinine < 400 mol/liter; 3.) plasma cholesterol > 7
mmollliter. All patients had a primary glomerular disease
proven by renal biopsy. Diabetes mellitus, thyroid disorders,
liver disease, pregnancy, amyloid and neoplasia were exclusion
criteria. Treatment with corticosteroids was also considered an
exclusion criterion although patients on diuretic and/or antihy-
pertensive therapy were included. Clinical details of the pa-
tients are given in Tables 1 and 2. A group of five normolipi-
demic volunteers was also studied. They were recruited from a
coronary screening program and were selected because of
homozygosity for the E3 polymorphism of apolipoprotein E.
This is the most common apo E phenotype, and since apo E
polymorphisms may influence apo B metabolism [20] these
subjects were selected as normal controls. Throughout the
studies patients were asked to follow their normal diets. None
of the proteinuric group had been prescribed a specific diet. The
study was approved by the Ethics Committee of Glasgow Royal
Infirmary.
The technique for performing apoB kinetic studies has been
described previously [21, 22]. Briefly, subjects were asked to
attend fasting and approximately 200 to 250 ml of plasma was
removed by plasmapheresis. Oral potassium iodate (170 mg
twice a day) was started and continued for four weeks to
suppress thyroidal uptake of radioiodide. VLDL (D < 1.006
g/ml) was recovered from the plasma by ultracentrifugation in a
Beckman Ti60 rotor (18 hr, 39000 rpm, 10°C). Total VLDL was
removed by aspiration of the top 2 to 4 ml from each 25 ml tube
and diluted with the infranatant salt solution to achieve a
lipoprotein concentration equivalent to a plasma triglyceride
level of 1.5 mmol/liter (for example, triglyceride 3 mmollliter —
dilute 1:2). This minimises carryover of VLDLI to VLDL2
during preparative ultracentrifugation. The solution density was
then raised to 1.118 g/ml by the addition of solid sodium
chloride (0.171 g/ml). Six 2 ml aliquots were subjected to
cumulative flotation ultracentrifugation on a discontinuous salt
gradient in a SW 40 rotor as adapted from Lindgren, Jensen and
Hatch 123]. VLDL1 (Sf60 to 400) and VLDL2 (Sf20 to 60) were
isolated by this method and aliquots (2 ml) were then labeled
with I and 125!, respectively, as previously described [24].
Free radioiodide and salt were removed by gel filtration on a
PD1O column (Pharmacia, Uppsala, Sweden) followed by ex-
tensive dialysis against 0.15 M NaCI pH 7.4. Three days after
plasmapheresis the subjects returned, having fasted for more
than 12 hours, and approximately 50 pCi of each tracer was
administered intravenously. The tracers were sterilized by
passage through a 0.45 micron filter (Acrodisc; Gelman Sci-
ence, Northampton, UK) immediately prior to injection. Blood
samples were collected at 10 minutes and then frequently over
the first 10 hours, after which a low fat meal was allowed.
Further samples were taken at 14 and 24 hours and then daily
fasting samples were obtained for 12 days. Each plasma sample
was subjected to ultracentrifugation as above to isolate four
fractions: VLDL1, VLDL2, IDL (Sf 12 to 20) and LDL (Sf0 to
12). ApoB was precipitated [25] from each fraction by the
addition of an equal volume of freshly-distilled 1,1,3,3-tetra-
methylurea (TMU). The pellet was then delipidated and the
apoB specific activity calculated from the protein content of the
precipitate redissolved in 0.5 M NaOH (measured by a modified
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Lowry assay [261), and the radioactivity counted in a twin
channel gamma counter (Canberra Packard, Pangbourne, UK).
The plasma concentration of each lipoprotein fraction was
estimated from the sum of the concentrations of lipids and
protein in each fraction isolated from pooled plasma. Total
cholesterol, free cholesterol, triglyceride and total phospholip-
ids were measured by enzymatic colorimetric assays (Boehr-
inger Mannheim, Lewes, East Sussex, UK). Protein was mea-
sured by the Lowry method [26]. The mass of each fraction was
corrected for ultracentrifugal losses by comparing the total
cholesterol recovered in the four fractions obtained by cumu-
lative flotation ultracentrifugation with the cholesterol content
of the non-HDL cholesterol measured by routine beta-quanti-
fication [27]. Recovery varied from 82 to 92% and the calculated
lipoprotein masses were each corrected by this factor. This
assumes that each fraction was lost in similar amounts and that
the different components of the lipoproteins were also lost in
equal proportion.
ApoB concentration was measured in aliquots of each frac-
tion by precipitating apoB with TMU and measuring the protein
content in the supernatant solution [25]. ApoB concentration
was derived from the difference between total and TMU-soluble
protein. Intravascular pool sizes of apoB were obtained from
the product of apoB concentration and plasma volume esti-
mated from the dilution of the VLDL2 tracer at ten minutes.
Steady state conditions of lipoprotein metabolism were con-
firmed by measurements of plasma lipid and lipoprotein levels
at regular intervals over the study period. The coefficient of
variation for each patient's plasma cholesterol level was <10%.
The figure for plasma triglyceride ranged up to 20%. Apolipo-
protein E phenotyping was performed by isoelectric focusing
[28, 29].
Kinetic analysis
The radioactivity in apoB in each lipoprotein fraction was
obtained by multiplying the specific activity (cpm/mg) at each
time point by the pool size (mg apoB) of the appropriate
fraction. All radioactivities were then expressed as a percentage
of the total apoB activity present in the 10 minute sample
calculated from the sum of radioactivity in VLDL1, VLDL2,
IDL and LDL. Plasma decay curves and pool sizes were then
analyzed by a multicompartmental model using the SAAM/
CONSAM 30 program [30, 31]. The rate constants and esti-
mated compartmental masses were used to derive fractional
transfer and catabolic rates, production rates for apoB in
VLDL1, VLDL2 and, where necessary, LDL and flux rates
between compartments. Production and flux rates are ex-
pressed as mg apoB/kg body weight/day. Fractional transfer
and catabolic rates are presented as pools/day.
The model used to analyse apoB metabolism in very low
lipoproteins has been described previously [22, 32]. In sum-
mary, it consists of two parallel pathways from large and small
VLDL (VLDL1 and VLDL2, respectively) through IDL to
LDL. The transfer of apoB along this chain is thought to be
dependent on stepwise delipidation mediated by lipase activity.
Direct input of apoB occurs both at VLDL1 and VLDL2. Where
the calculated mass in LDL derived from these precursors falls
significantly short (>10%) of the measured mass, direct synthe-
sis of LDL is invoked. Removal of apoB occurs at each level of
the pathway. This model, however, did not allow an adequate
fit of the data from the proteinuric group in that the calculated
pool mass for VLDL1 was underestimated in a number of these
subjects who had an expanded VLDL1 pool. Several subjects
also demonstrated a biexponential decay of VLDL1, suggesting
the presence of an additional slowly metabolized component
within this fraction. A revised model was therefore developed
for the nephrotic subjects (Fig. 1). The numbering of these
compartments reflects the evolution of the mathematical model
and is presented in the form used in these studies. In this
version, VLDL1 is composed of three compartments with input
to and direct removal from two parallel pathways one of which
does not feed into the delipidation chain and contribute to the
mass of other lipoprotein fractions. These extra compartments
(29 and 26) were not required for the analysis of the control
subjects.
Statistical analysis
Non-parametric methods were used because of the small
numbers and the wide spread of results in the nephrotic group.
Results are shown as medians and ranges. Differences between
nephrotic and control groups were tested by the Mann-Whitney
U test and correlations by Spearman's rank test. The plots
comparing the specific activities of the two tracers between the
groups are shown as mean and standard deviations. The com-
positional data for both groups were of comparable variance
and were analyzed by a two-sample t-test.
Results
This group of patients with moderate to heavy proteinuria
demonstrated variable rises in plasma cholesterol and triglyc-
eride (Table 3). Serum albumin was remarkably well maintained
even when quantitative proteinuria approached 10 g/day, and
the inverse relationship between serum albumin and plasma
cholesterol often seen in nephrotic syndrome did not exist.
LDL cholesterol was moderately elevated in seven patients
with one patient (JG) having a very high level of 10.0 mmollliter.
VLDL cholesterol was high in three patients who all demon-
strated a relatively high VLDL cholesterol/plasma triglyceride
ratio. One of these patients (WS) possessed an E2 allele of the
apoE polymorphism. The increased plasma lipid levels were
reflected in increased concentrations of VLDL2, IDL and LDL.
VLDL1 was not significantly increased (Fig. 2). There were no
significant differences in the relative composition of all four
lipoprotein fractions between controls and proteinuric subjects
(data not shown).
Kinetic studies
Figure 3 compares the metabolism of apoB from each tracer
in the four subfractions by plotting the mean radioactivity at
each time point for both proteinuric and control groups. The
results of the kinetic analysis are presented in Tables 4A to D.
VLDLJ
The ''i VLDL1 apoB tracer was cleared more slowly in the
nephrotic group than in controls primarily due to a consistent
reduction in the fractional transfer of VLDL1 apoB to VLDLI
(median 0.92; range 0.22 to 3.31 vs. 3.66; 2.48 to 5.16, P <0.02;
Table 4A). Both nephrotic and control groups showed wide
variation in the fraction of the VLDL1 apoB pool which was
catabolized directly from the plasma compartment. In the
Fig. 1. Model of lipoprotein metabolism used for multicomparimental
analysis. This model has been built up over several years from apob
kinetic studies in various dyslipidemic conditions. ApoB production
occurs in both VLDLI and in VLDL2, which is shown as U29/U26 and
U12, respectively. Parallel pathways are shown for apoB derived from
the two VLDL species. ApoB is transferred along a delipidation chain
or removed from the system according to the arrows. The metabolic
pathways are considered to be unidirectional and to follow first order
kinetics.
proteinuric group, the VLDL1 apoB pooi size varied from
normal to eight times normal and this was related to plasma
triglyceride level (Table 3). The calculated rate of apoB flux
from the large triglyceride rich VLDL1 to smaller VLDL2 was
reduced significantly (1.9 mg/kg/day; 1.1 to 2.9 vs. 2.7; 1.8 to
5.1, P < 0.05) even in those patients with normal pool sizes
(CF. MD, RG, JG). There was wide variation in the secretion of
apoB into VLDL1 (2.6 to 64.8 mg/kg/day) in the proteinuric
group. Although four patients had very high production rates,
there were no statistically significant differences between the
groups.
VLDL2
The VLDL2 apoB tracer was also cleared from the plasma of
the nephrotic group at a slower rate than normal. This was seen
with both tracers, that is, directly labeled VLDL2 and the
material transferred from VLDL1 (Fig. 3B and 3E). Again this
was attributable to a reduced delipidation rate to IDL (or LDL
by pathways l2—2l and 4—*20; Table 4B). Direct removal of
VLDL2 apoB from plasma was highly variable and not signifi-
cantly different between the two groups. The VLDL2 apoB pool
was expanded in the proteinuric group (2 to 3 x normal) mainly
due to a marked increase in de novo synthesis of apoB in
VLDL2 (14.5 mg/kg/day; 5.1 to 32.2 vs. 4.2; 2.9 to 8.8, P <
0.02). Reduced catabolism made a relatively smaller contribu-
tion to the expansion of the pool size. The larger VLDL2 pool
led to a modest increase in the amount of IDL apoB formation,
although this was not statistically significant (10.4 mg/kg/day;
4.4 to 17.2 vs. 5.8; 2.7 to 8.7; P = 0.12). This occurred despite
the reduced fractional transfer rate from VLDL2 to IDL.
IDL
The mean plasma radioactivity curves for 125J and 1311
reached comparable peak values in IDL at similar times for
both groups (Fig. 3 C and F). Thereafter, the curves diverged
with the normals showing an initial more rapid decay that was
due to direct catabolism of the lipoprotein (Table 4C). There
was no obvious difference in the rate at which both groups of
subjects accumulated 1251 and ''i in LDL apoB, indicating a
similar degree of IDL to LDL conversion (Table 4C). The
expansion of the IDL apoB pool in nephrotics was due to a
combination of increased synthesis from VLDL2 and dimin-
ished direct removal. This had the net effect of channeling an
increased amount of apoB from IDL to LDL (Table 4D).
LDL
The appearance curves for 1251 and 131J apoB radioactivity in
LDL were similar for control and nephrotic groups (Fig. 3 D
and G). Peak values were achieved at a later time in the latter
group but the extent of transfer from VLDL1 and VLDL2 was
approximately the same. The most pronounced difference in the
curves was delayed clearance of both tracers from the LDL of
nephrotic subjects. Normal subjects had a biphasic LDL decay
curve consisting of a relatively rapid catabolism up to 120
hours, and then a slower terminal phase. Visual inspection of
the averaged data from the patients with nephrotic syndrome
indicated a lack of the early rapid phase of LDL degradation.
The observed fractional catabolic rate for LDL should be
corrected for urinary loss of whole lipoprotein. This is not
possible to determine from urine collections during a VLDL
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1251-VLDL2
U29
$
1311-VLDL1
VLDL1
Sf 60-400
VLDL2
Sf 20-60
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Table 3. Plasma lipid and lipoprotein concentrations
Subject
E/E
phenotype
Cholesterol Triglyceride VLDL-cholesterol LDL-cholesterol HDL-cholesterol VLDL-cholesterol:plasma triglycende
ratio
apoB poola
size
mgmmol/liter
Nephrotic
CM 4/3 9.4 4.5 3.0 5.4 1.1 0.67 4306
AP 4/3 8.6 3.5 1.6 6.0 1.0 0.46 5718
WS 3/2 8.6 3.4 3.0 4.8 0.8 0.88 5061
JG 3/3 12.8 3.1 2.1 10.0 0.8 0.68 4848
JH 3/3 8.3 2.8 1.1 6.0 0.9 0.38 3181
MD 3/3 7.3 1.9 0.9 4.9 1.5 0.47 2038
RG 3/3 7.3 1.6 0,6 5.4 1.3 0.38 4796
CF 4/3 7.6 1.2 0.6 5.4 1.7 0.46 2640
Controls
NC 3/3 5.0 1.7 0.8 3.1 1.0 0.46 1970
CD 3/3 6.2 2.6 1.0 4.1 1.4 0.40 2860
MF 3/3 5.8 1.1 0.6 4.0 1.2 0.56 3000
EK 3/3 5.0 1.0 0.4 2.8 1.9 0.37 1450
MM 3/3 5.6 2.2 1.0 3.7 1.2 0.45 2270
0
Fig. 2. Plasma concentrations of lipoprotein
subfractions prepared by cumulative flotation
ultracentrfugation calculated from the sum of
the compositional analysis. Open circles (0)
represent nephrotic subjects and closed circles
controls (•). P values represent comparisons
between control and nephrotic groups:
VLDLI P = NS; VLDL2 P < 0.03; IDL P <
0.01; LDL P < 0.02.
turnover because a high proportion of injected radioactivity is
present in components other than apoB (that is, apolipoproteins
C and E and lipids). In a previous study of trace-labeled LDL in
nephrotic syndrome [19], we estimated the average urinary
excretion of undegraded lipoprotein as 7% of total urine radio-
activity; the values in Table 4D overestimate the true FCR by
this proportion. The LDL FCR was subnormal in most of the
disease group, but three (CM, WS and CF) showed normal or
even high values, and overall there was no significant difference
from controls even when corrected for estimated urinary losses.
Likewise, there was a variable expansion of the LDL apoB
pool. Its size ranged from normal to twice normal. The produc-
tion of LDL from VLDL2 and IDL was significantly increased
in the nephrotic group compared to normal.
Discussion
Hyperlipidemia is common in nephrotic syndrome. Despite
this its origins remain unexplained. Most investigators have
considered that the major pathogenic mechanism is increased
hepatic synthesis and secretion of lipoproteins [33]. The stim-
ulus for this may be decreased serum albumin, either directly or
indirectly via changes in plasma oncotic pressure [34] or vis-
cosity. It has been suggested that there is a non-specific
increase in hepatic protein synthesis in response to these
factors. However, recently Kaysen et al [35] have examined the
relationship between hyperlipidemia and albumin synthetic
rates. By replacing a high protein with a low protein diet in
patients with nephrotic syndrome, mean albumin synthetic
rates were reduced from 17.60 to 12.61 g/l.73 m2/day, which is
in the low/normal range. Although lipoprotein synthetic rates
were not measured directly, hyperlipidemia persisted in the
face of normal albumin synthetic rates.
Reduced lipoprotein catabolism has also been described in
nephrotic syndrome. Several lines of evidence suggest that
catabolic defects are present along the VLDL—IDL--*LDL
a Sum of apo B pools in the four lipoprotein fractions
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delipidation cascade. Early work by Gitlin et a! [5] demon
strated a delay in the catabolism of radioiodinated Sf100 to 400
lipoproteins. More recently Vega and Grundy [171 have shown
reduced clearance of a combined VLDL and IDL tracer (D <
1.019 gIml) in four nephrotic subjects compared to controls. The
delipidation of VLDL is catalyzed by endothelium-bound Ii-
pases in hepatic and extra-hepatic tissues (skeletal muscle and
adipose tissue). Decreased activities of these enzymes have
been reported in this disorder [36—39], although this finding has
not always been confirmed [40—42]. Our own study of LDL
metabolism in nephrotic syndrome [191 emphasized the de-
creased catabolic rate of the lipoprotein as the major contribu-
tor to the elevated plasma levels in the majority of subjects
investigated. These observations imply that the metabolic dis-
turbances in the lipoprotein transport system in this condition
are complex. This led us to undertake the present detailed
investigation of apoB kinetics in the nephrotic syndrome.
The eight subjects studied had persistent heavy proteinuria
and had been followed up for a period varying from 10 months
to 35 years (Table 1). They had moderate hyperlipidemia except
for JG who had a markedly elevated LDL cholesterol level.
Plasma triglyceride levels varied from low normal (1.2 mmol/
liter) to high (4.5 mmol/liter), emphasizing the heterogeneous
nature of the study group. Previous larger, cross sectional
studies of the incidence of hyperlipidemia in nephrotic syn-
drome [9, 10] have generally reported relationships between
hyperlipidemia and severity of nephrotic syndrome (hypoalbu-
minemia or proteinuria). These associations were not found in
this study, but this probably reflects the small numbers which
can be practically studied in lipoprotein kinetic investigations.
When apoB-containing lipoproteins were fractionated by cumu-
lative flotation ultracentrifugation significant increases were
seen in plasma levels of VLDL2, IDL and LDL (Fig. 3). The
composition of all four lipoprotein fractions was normal, indi-
cating that there was no substantial accumulation of cholesterol
ester-rich VLDL remnants in the VLDL2 and IDL density
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Table 4A. Kinetic parameters of apo B metabolism in VLDLI
Subject
Fractional catabolism
Production Pool size pools/day
mg/kg/day mg Direct to VLDL2
Nephrotic
CM
AP
WS
JO
JH
MD
RG
CF
Median
25.3 413 4.54 0.22
11.9 297 3.11 0.85
7.8 210 1.74 1.02
64.8 117 30.6 1.05
2.8 195 0.58 0.74
34.5 83 19.5 0.70
23.0 87 20.1 1.01
2.6 46 0.04 3.33
17.5 156 3.83 0.93
Controls
NC
CD
MF
EK
MM
Median
P
8.8 67 4.17 5.16
6.1 52 5.75 4.49
14.5 97 10.8 2.48
11.5 47 14.7 2.71
14.7 106 6.91 3.66
11.5 67 6.91 3.66
NS NS NS <0.02
Table 4B. Kinetic parameters of apo B metabolism in VLDL2
Subject
Fractional
catabolism
pools/day
Production mg/kg/day Pool size To
Direct From VLDLJ mg Direct IDL
Nephrotic
CM
AP
WS
JO
JH
MD
RG
CF
Median
14.6 1.2 642 0.44 1.43
15.7 2.6 714 1.40 1.11
14.5 2.9 570 0.03 2.26
11.2 2.2 488 0.0 1.54
5.1 1.6 336 0.61 1.18
32.2 1.2 162 8.44 1.66
17.3 1.1 505 1.55 1.36
9.8 2.5 233 0.12 3.12
14.5 1.9 497 0.53 1.49
Controls
NC
CD
MF
EK
MM
Median
P
4.2 4.9 160 0.18 3.88
8.8 2.7 231 2.14 2.14
5.6 2.7 199 0.92 2.81
2.9 1.8 69 2.14 2.74
3.7 5.1 218 1.15 1.93
4.2 2.7 199 1.15 2.74
<0.02 <0.05 <0.02 NS <0.05
ranges despite high plasma triglyceride/VLDL cholesterol ra-
tios in some patients.
Three significant perturbations of apolipoprotein B metabo-
lism were noted in the nephrotic subjects. First, the rates of
transfer of VLDL1 apoB to VLDL2 and of VLDL2 apoB to IDL
were reduced. This was true even in normotriglyceridemic
nephrotic subjects (MD, RG, CF in Table 4A) who had normal
VLDLI apoB pooi sizes. Thus the delayed clearance could not
be due simply to saturation of the delipidation mechanism.
These metabolic steps are believed to involve the action of
lipoprotein lipase and, to some extent, hepatic triglyceride
Table 4C. Kinetic parameters of apo B metabolism in IDL
Subject
Production
from VLDL2
mg/kg/day
Pool size
mg
Fractional
catabolism
pools/day
To
Direct IDL
Nephrotic
CM
AP
WS
JO
JH
MD
RO
CF
Median
11.9
8.1
17.2
12.0
4.4
5.5
8.5
11.7
10.4
730
1131
1122
595
554
322
754
527
663
0.02 1.2
0.01 0.69
0.58 0.56
0.09 1.15
0.0 0.71
0.08 0.75
0.02 0,88
0.21 1.13
0.05 0.82
Controls
NC
CD
MF
EK
MM
Median
P
8.7
5.8
5.8
2.7
5.1
5.8
NS
241
408
358
174
351
351
<0.05
0.76 1.80
0.18 1.02
0.26 1.17
0.37 0.68
0.33 0.76
0.33 1.02
<0.05 NS
Table 4D. Kinetic parameters of apo B metabolism in LDL
Production mg/kg/day Pool
size
Fractional
catabolism
Total apo B
productionFrom VLDL2
Subject Direct and IDL mg pools/day mg/kg/day
Nephrotic
CM 4.8 11.9 2623 0.49 44.8
AP 0.0 8.0 3617 0.22 27.6
WS 4.7 8.4 3187 0.32 27.2
JO 0.0 12.4 3426 0.21 76.1
JH 0.0 4.6 2247 0.18 8.0
MD 0.0 4.9 1315 0.18 66.7
RG 0.0 8.4 3129 0.22 40.3
CF 0.0 10.0 1842 0.33 12.3
Median 0.0 8,4 2876 0.22 33.9
Controls
NC 0.0 6.1 1433 0.30 11.4
CD 2.7 4,9 2505 0.26 13.7
MF 0.1 5.2 2044 0.23 13.4
EK 2.6 1.7 1160 0.26 14.3
MM 2.0 4.0 1620 0.28 14.9
Median 2.0 4.7 1620 0.26 13.7
P NS NS NS NS NS
P value by Mann-Whitney comparing groups. Significance taken as P
<0.05.
lipase [22]. As noted above, a number of studies in both human
and experimental nephrotic syndrome have examined post-
heparin plasma lipase activities with contradictory results.
Chan and co-workers [39], using a substrate-specific method,
documented a decrease in lipoprotein lipase with normal he-
patic triglyceride lipase activity, while Oetliker et al [42] could
not find any significant difference compared to controls for
either enzyme using a more standard immunoinhibition method.
In vitro, nephrotic serum appears to be able to inhibit lipase
activity [39]; a similar finding has been reported in uremia.
However, the degree of inhibition did not correlate with reduc-
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tions in lipase activity in the patients. Several hypotheses have
been advanced to explain the possible reduced lipase activity.
Apolipoprotein CII, an important activator of lipoprotein 11-
pase, has been isolated from nephrotic urine. However, esti-
mates of total plasma levels have not confirmed a reduced
concentration although recently Kashyap et a! [43] have re-
ported that the absolute amount associated with VLDL is
reduced. Alterations of the apolipoprotein composition of
VLDL may alter its catabolic potential, and account for a
recent report that VLDL from nephrotic rats has a reduced
clearance rate in normal animals and is more resistant to
lipolysis in vitro [44]. Two other explanations have been
proposed. Staprans and co-workers [45] isolated a separate
lipase co-factor from the urine of nephrotic patients which they
identified as a glycosaminoglycan, and Bernard [1] has re-
viewed the possibility that in hypoalbuminemic states de-
creased removal of free fatty acids which are normally protein-
bound may impair lipolysis.
Second, the synthesis of apoB in the density interval of
VLDL2 was increased several-fold on average. This effect was
more consistent than the highly variable values seen for VLDL1
apoB synthesis in the nephrotic subjects. The increased direct
synthesis (Table 4B) more than compensated for the reduced
flux from VLDL1. This in turn led to overproduction of IDL and
LDL (Table 4 C and D). Thus, hepatic oversynthesis of apoB
was a feature of this group and contributed to the expansion of
the VLDL,, IDL and LDL pools. As discussed above, hepatic
oversynthesis of apoB-containing lipoproteins is a feature of
animal models of nephrotic syndrome [33, 45—491 and has also
been reported in humans [50]. In the latter study [50], markedly
increased rates of apolipoprotein B production were found in a
group of severely hyperlipidemic nephrotic patients, although
the full details of these subjects have not been reported. The
stimulus to overproduction is unclear. However, in the current
study, the finding that triglyceride-poor VLDL2 rather than
is overproduced suggests that increased hepatic apo-
lipoprotein rather than triglyceride synthesis was responsible
for the elevation in plasma VLDL. This contrasts with the
kinetic changes that underly the hypertriglyceridemia of non-
insulin-dependent diabetes mellitus [51]. In this condition
larger, lipid-rich VLDLJ particles are secreted in excessive
amounts but insulin therapy results in a decrease in VLDL1
production and an increase in VLDL2. This is thought to reflect
limitation of carbohydrate and free fatty acid flux to the liver,
which in the insulin-deficient state stimulates hepatic triglycer-
ide synthesis and production of VLDL1.
The third abnormality observed in nephrotic subjects was a
reduced clearance rate (FCR) for both IDL and LDL (Table 4 C
and D). The reduction was consistent and significantly different
from normal for IDL, whereas the LDL FCR varied from
subnormal values in five patients (AP, JG, JH, MD and RG)
through normal (WS and CF) to an elevated level in CM.
Overall there was a trend towards lower LDL catabolic rates in
the nephrotic group in keeping with previous studies [17, 19],
although there was no statistically significant reduction. We
believe that patient selection may have contributed to the lack
of a significant reduction in the LDL FCR compared to the
control group, since the present group did not exhibit as severe
hypercholesterolemia as our previous study (mean LDL cho-
lesterol 6.0 mmol/liter vs. 7.5 mmol/liter). In addition, there are
methodological differences between the two studies. LDL
studied using the cumulative flotation ultracentnfugation tech-
nique often displays a lower FCR compared to LDL prepared
by rate zonal ultracentrifugation or fixed angle centrifugation.
Indeed, the values obtained for the control group are lower than
published data utilizing radiolabeled apoLDL as a tracer.
Synthesis of LDL apoB was found to be higher than normal,
but unlike Vega and Grundy [17], we did not require a signifi-
cantly increased level of direct LDL apoB synthesis. In most
subjects all of the apoB in LDL of nephrotics could be ac-
counted for by delipidation of VLDL and IDL.
The results of this study expand our current knowledge of the
abnormalities in lipoprotein metabolism in the nephrotic syn-
drome. Increased hepatic synthesis of apoB-containing lipopro-
teins at the level of VLDL2 was a feature of the syndrome, and
this together with a diminished capacity to catabolize IDL and
LDL led to the hypercholesterolemia observed in these sub-
jects. Elevation of plasma triglyceride was associated with high
concentrations of the large triglyceride-rich VLDL1 which
derived again from a combination of overproduction and a
reduced delipidation rate. It should be noted that this group of
patients studied was atypical in some respects with well-
maintained serum albumin despite heavy proteinuria. The ex-
planation for this is not clear; it is unusual but not unknown for
patients with moderately heavy proteinuria to maintain serum
albumin > 35 g/liter. Hypoalbuminemia has been most closely
correlated with hyperlipidemia in this condition. The absence of
severe hypoalbuminemia in our patients is reflected in the
relatively modest elevations of plasma and LDL cholesterol and
of LDL apoB pools. On the basis of our previous study we
predict that an increase in LDL to a level more commonly
found in nephrotic syndrome would be accompanied by further
reduction in the fractional catabolic rate of the lipoprotein.
Renal failure is associated with a different spectrum of lipid
and lipoprotein abnormalities than is found in the nephrotic
syndrome. Elevations of plasma triglycerides, reduced HDL-
cholesterol and normal or marginally elevated LDL-cholesterol
concentrations are the typical findings, and some of these
changes have been reported with mild renal impairment [52].
We attempted to minimize the effect of renal failure by restrict-
ing this study to patients with only modestly elevated serum
creatinine concentrations. One patient studied did have serum
creatinine > 400 mol/liter, but had a lipoprotein profile typical
of the nephrotic syndrome with markedly raised LDL. Al-
though this patient had a high rate of apoB synthesis in VLDL1,
other kinetic parameters did not show any systematic differ-
ences from those with well-maintained renal function.
Further studies comparing well defined groups of nephrotic
subjects on the basis of proteinuria, serum albumin, renal
function and lipoprotein patterns together with comparisons of
patients in relapse and remission of minimal change disease
would be useful. The advent of methods involving stable
isotopes [53] will permit more extensive and repeated applica-
tions of these techniques.
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Appendix 2. Calculated masses and inputs
M(1) M(26) M(29) M(2) M(4) M(6) M(12) M(13) M(15) M(17) M(20) M(21) U(26) U(29/1) U(12)
Subject
CM
AP
WS
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JH
MD
RG
CF
Median
19
256
86
22
40
14
11
7
21
391
1
111
90
0
66
73
0
70
3
40
13
5
155
3
3
39
9
70
122
210
212
46
22
37
60
65
2
90
190
2
53
4
6
15
11
16
74
29
0
43
9
21
5
19
555
428
141
274
194
127
441
153
234
62
176
239
121
128
41
54
258
125
668
955
883
455
426
281
700
269
562
0
0
0
19
0
0
0
0
0
115
305
263
325
265
57
85
405
264
1743
3312
1756
3101
1982
1258
3044
1437
2716
1877
1
134
3577
0
1584
1752
0
859
72
1166
446
120
256
108
87
158
139
1121
1541
1090
638
462
1576
1385
595
1106
Controls
NC
CD
MF
EK
MM
Median
67
51
97
47
106
67
0
0
0
0
0
0
0
0
0
0
0
0
56
32
34
18
43
34
52
48
62
11
99
52
3
3
6
6
2
3
50
148
98
39
70
70
81
56
148
42
231
81
66
256
199
76
114
76
94
95
11
56
5
56
793
417
920
231
485
485
640
1206
1124
219
606
640
0
0
0
0
0
0
625
522
1288
1120
819
819
301
761
500
203
280
301
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